全文获取类型
收费全文 | 92626篇 |
免费 | 7792篇 |
国内免费 | 4080篇 |
专业分类
耳鼻咽喉 | 533篇 |
儿科学 | 2460篇 |
妇产科学 | 1720篇 |
基础医学 | 20689篇 |
口腔科学 | 1954篇 |
临床医学 | 7181篇 |
内科学 | 17923篇 |
皮肤病学 | 1768篇 |
神经病学 | 3873篇 |
特种医学 | 1633篇 |
外国民族医学 | 26篇 |
外科学 | 5067篇 |
综合类 | 12782篇 |
现状与发展 | 27篇 |
一般理论 | 12篇 |
预防医学 | 11033篇 |
眼科学 | 1311篇 |
药学 | 7481篇 |
33篇 | |
中国医学 | 1850篇 |
肿瘤学 | 5142篇 |
出版年
2024年 | 108篇 |
2023年 | 1061篇 |
2022年 | 2741篇 |
2021年 | 3514篇 |
2020年 | 2937篇 |
2019年 | 2731篇 |
2018年 | 2695篇 |
2017年 | 2818篇 |
2016年 | 3169篇 |
2015年 | 3511篇 |
2014年 | 5113篇 |
2013年 | 6141篇 |
2012年 | 5045篇 |
2011年 | 5822篇 |
2010年 | 4882篇 |
2009年 | 4536篇 |
2008年 | 4407篇 |
2007年 | 4673篇 |
2006年 | 4295篇 |
2005年 | 3822篇 |
2004年 | 3467篇 |
2003年 | 3048篇 |
2002年 | 2525篇 |
2001年 | 2325篇 |
2000年 | 1930篇 |
1999年 | 1712篇 |
1998年 | 1582篇 |
1997年 | 1583篇 |
1996年 | 1390篇 |
1995年 | 1360篇 |
1994年 | 1242篇 |
1993年 | 1066篇 |
1992年 | 876篇 |
1991年 | 793篇 |
1990年 | 633篇 |
1989年 | 594篇 |
1988年 | 557篇 |
1987年 | 405篇 |
1986年 | 365篇 |
1985年 | 651篇 |
1984年 | 498篇 |
1983年 | 351篇 |
1982年 | 376篇 |
1981年 | 292篇 |
1980年 | 223篇 |
1979年 | 156篇 |
1978年 | 155篇 |
1977年 | 99篇 |
1976年 | 93篇 |
1975年 | 40篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
51.
《Saudi Pharmaceutical Journal》2020,28(10):1243-1252
The novel coronavirus outbreak has reported to be rapidly spreading across the countries and becomes a foremost community health alarm. At present, no vaccine or specific drug is on hand for the treatment of this infectious disease. This review investigates the drugs, which are being evaluated and found to be effective against nCOVID-19 infection. A thorough literature search was performedon the recently published research papers in between January 2020 to May 2020, through various databases like “Science Direct”, “Google Scholar”, “PubMed”,“Medline”, “Web of Science”, and “World Health Organization (WHO)”. We reviewed and documented the information related with the current and future aspects for the management and cure of COVID-19. As of 21st July 2020 a total of 14,562,550 confirmed cases of coronavirus and 607,781 deaths have been reported world-wide. The main clinical feature of COVID-19 ranges from asymptomatic disease to mild lower respiratory tract illness to severe pneumonia, acute lung injury, acute respiratory distress syndrome (ARDS), multiple organ dysfunction, and death. The drugs at present used in COVID-19 patients and ongoing clinical trials focusing on drug repurposing of various therapeutic classes of drug e.g. antiviral, anti-inflammatory and/or immunomodulatory drugs along with adjuvant/supportive care. Many drugs on clinical trials shows effective results on preliminary scale and now used currently in patients. Adjuvant/supportive care therapy are used in patients to get the best results in order to minimize the short and long-term complications. However, further studies and clinical trials are needed on large scale of population to reach any firm conclusion in terms of its efficacy and safety. 相似文献
52.
53.
54.
Auda A. Eltahla Fabio Luciani Peter A. White Andrew R. Lloyd Rowena A. Bull 《Viruses》2015,7(10):5206-5224
The hepatitis C virus (HCV) is a pandemic human pathogen posing a substantial health and economic burden in both developing and developed countries. Controlling the spread of HCV through behavioural prevention strategies has met with limited success and vaccine development remains slow. The development of antiviral therapeutic agents has also been challenging, primarily due to the lack of efficient cell culture and animal models for all HCV genotypes, as well as the large genetic diversity between HCV strains. On the other hand, the use of interferon-α-based treatments in combination with the guanosine analogue, ribavirin, achieved limited success, and widespread use of these therapies has been hampered by prevalent side effects. For more than a decade, the HCV RNA-dependent RNA polymerase (RdRp) has been targeted for antiviral development. Direct acting antivirals (DAA) have been identified which bind to one of at least six RdRp inhibitor-binding sites, and are now becoming a mainstay of highly effective and well tolerated antiviral treatment for HCV infection. Here we review the different classes of RdRp inhibitors and their mode of action against HCV. Furthermore, the mechanism of antiviral resistance to each class is described, including naturally occurring resistance-associated variants (RAVs) in different viral strains and genotypes. Finally, we review the impact of these RAVs on treatment outcomes with the newly developed regimens. 相似文献
55.
《Vaccine》2016,34(8):1115-1125
Chronic hepatitis C virus (HCV) infection represents a major health threat to global population. In India, approximately 15–20% of cases of chronic liver diseases are caused by HCV infection. Although, new drug treatments hold great promise for HCV eradication in infected individuals, the treatments are highly expensive. A vaccine for preventing or treating HCV infection would be of great value, particularly in developing countries. Several preclinical trials of virus-like particle (VLP) based vaccine strategies are in progress throughout the world. Previously, using baculovirus based system, we have reported the production of hepatitis C virus-like particles (HCV-LPs) encoding structural proteins for genotype 3a, which is prevalent in India. In the present study, we have generated HCV-LPs using adenovirus based system and tried different immunization strategies by using combinations of both kinds of HCV-LPs with other genotype 3a-based immunogens. HCV-LPs and peptides based ELISAs were used to evaluate antibody responses generated by these combinations. Cell-mediated immune responses were measured by using T-cell proliferation assay and intracellular cytokine staining. We observed that administration of recombinant adenoviruses expressing HCV structural proteins as final booster enhances both antibody as well as T-cell responses. Additionally, reduction of binding of VLP and JFH1 virus to human hepatocellular carcinoma cells demonstrated the presence of neutralizing antibodies in immunized sera. Taken together, our results suggest that the combined regimen of VLP followed by recombinant adenovirus could more effectively inhibit HCV infection, endorsing the novel vaccine strategy. 相似文献
56.
目的鉴定河南省1例来自柬埔寨的登革热输入性病例的登革病毒(dengue virus,DENV)血清型和基因型及其序列特征和传播来源。方法患者血液标本来源于2019年国家疾病监测系统网络直报的登革热疑似病例。样品经快速检测DENV NS1抗原和IgM/IgG抗体,再提取血清中核酸,应用荧光RT-PCR法进行DENV血清型鉴定,同时用Vero和BHK-21细胞对血清标本进行病毒分离培养,阳性培养物扩增全基因组序列,进行序列系统进化分析。结果该病例实验室确诊为DENV 1型感染,并从血清标本中分离到病毒株,测序后拼接成全长10670 nt的全基因组序列,经系统进化分析,该病毒株属于DENV 1型基因Ⅰ型,与东南亚流行株具有较高同源性和较近亲缘关系。结论2019年河南省来自柬埔寨的输入性病例的病原体为DENV 1型基因I型,此为近年来东南亚输入我国的常见血清型和基因型。 相似文献
57.
58.
丙型肝炎病毒(HCV)感染在慢性肾功能不全患者中较常见,尤其是在进行透析的患者中,HCV感染较普通患者的风险极大增加,同时还会导致肝细胞癌及肝硬化的发病率明显升高。近年来直接抗病毒药物(DAAs)在慢性丙型肝炎的治疗中取得了较好的疗效及安全性,本文通过总结DAAs在丙型肝炎合并透析患者中的应用进展,发现对于基因1~6型HCV合并透析患者,推荐使用G/P方案;由于索磷布韦(SOF)经肾脏代谢,在重度肾损害人群中的血药浓度较高,因此SOF组合方案并不推荐用于丙型肝炎合并透析患者的治疗。 相似文献
59.
Background Limited research exists on patient knowledge/cognition or “getting inside patients'' heads.” Because patients possess unique and privileged knowledge, clinicians need this information to make patient-centered and coordinated treatment planning decisions. To achieve patient-centered care, we characterize patient knowledge and contributions to the clinical information space. Methods and Objectives In a theoretical overview, we explore the relevance of patient knowledge to care provision, apply historical perspectives of knowledge acquisition to patient knowledge, propose a representation of patient knowledge types across the continuum of care, and include illustrative vignettes about Mr. Jones. We highlight how the field of human factors (a core competency of health informatics) provides a perspective and methods for eliciting and characterizing patient knowledge. Conclusion Patients play a vital role in the clinical information space by possessing and sharing unique knowledge relevant to the clinical picture. Without a patient''s contributions, the clinical picture of the patient is incomplete. A human factors perspective informs patient-centered care and health information technology solutions to support clinical information sharing. 相似文献
60.
Expression of TRIM22 mRNA in chronic hepatitis C patients treated with direct-acting antiviral drugs
Mariam Naveed Amjad Ali Nadeem Sheikh Shazia Rafique Muhammad Idrees 《APMIS : acta pathologica, microbiologica, et immunologica Scandinavica》2020,128(4):326-334
Hepatitis C is a global public health problem, and Pakistan is the second largest country in the globe with highest prevalence rate of hepatitis C virus (HCV). Until 2014, pegylated interferon (PEG-IFN) plus ribavirin (RBV) has been the standard therapy for HCV, however, owing to its adverse side effects and very low sustained virologic response (SVR) rates therapeutics trend is shifted toward direct-acting antivirals. Tripartite motif containing 22 (TRIM22) is a dynamic antiviral protein that can inhibit multiple viruses in vivo. Expression of TRIM22 mRNA has been linked to outcome of PEG-IFN and ribavirin therapy, where its higher expression leads to rapid virus clearance. However, in terms of therapy with direct-acting antiviral (DAA) or double DAA, impact of TRIM22 expression is largely unknown. These new drugs show more than 90% of SVR rates and lesser side effects and have proven to be better than IFN therapy. Endogenous IFN system suppresses various pathogens through the induction of antiviral effectors termed as interferon-stimulating genes (ISGs). We have studied the expression levels of one of these antiviral effectors, TRIM22 in response to sofosbuvir (SOF) and daclatasvir (DAC) in combination with RBV, using quantitative PCR in the peripheral blood mononuclear cells (PBMCs) of HCV-infected patients. We have observed sustained virus clearance in more than 90% of patients treated with DAA and double DAA and have seen the expression of TRIM22 to be higher in patients who attained SVR as compared to the untreated patients. We have also observed downregulation of TRIM22 in patients who failed to attain rapid virus clearance, and upregulation in those who achieved rapid clearance of virus. Genetic factors that determine the lower TRIM22 expression in these patients are needed to be explored that may also play a role in lower response to anti-HCV therapy. Endogenous IFN system and effects of antiviral proteins in response to DAA therapy is needed to be studied in order to better understand the host response toward these drugs to make them more effective. 相似文献